Sept. 5–6, 2019 • Houston, Texas
In the wake of the 2017 U.S. Food and Drug Administration approvals for Chimeric Antigen Receptor (CAR) T cell therapies for the treatment of patients with lymphoma and leukemia, adoptive cellular therapies have rapidly become a focal point for stakeholders across the field of cancer immunotherapy.
As this treatment modality has displayed unprecedented patient response and offers significant curative potential for cancer patients across the globe, SITC was proud to host an Adoptive Cellular Therapies Workshop to support both continued momentum and clinical advancement.
This two-day workshop brought together cancer immunotherapy experts to discuss and address challenges concerning the use and development of adoptive cellular therapies for the treatment of cancer patients.
Throughout seven didactic sessions and participation in collaborative working groups, attendees discussed a number of topics, including:
- Development of novel strategies to improve the overall risk/benefit profile for adoptive cellular therapies
- Clinical development and regulatory challenges
- Real world hurdles that impact scalability and patient access
It is anticipated that the efforts of this workshop, and the resulting manuscript, will help fuel innovative collaborative efforts as well as the dissemination of knowledge throughout the field.
Alessandra Cesano, MD, PhD – ESSA Pharma Inc.
Katayoun Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center
Who should attend?
- Clinicians and researchers from academia, non-profit organizations, and industry
- Regulators and reimbursement experts
Upon completion of this meeting, participants will be able to:
- Explain the status and direction of the field of adoptive cellular therapy.
- Identify high relevant challenges and questions from science to real word clinical application of ACT.
- Describe the challenges related to cost, monitoring and safety concerns regarding genetically modified products.
- Summarize manufacturing scalability, patient access, product cost and treatment reimbursement concerns.
This program has been supported, in part, by grants from Celgene Corporation, Kite, A Gilead Company, NanoString Technologies, Inc., Pfizer, Inc., and Refuge Biotechnologies.